Picture of Bionano Genomics logo

BNGO — Bionano Genomics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Bionano Genomics Inc expected to post a loss of 11 cents a share - Earnings Preview

* Bionano Genomics Inc  BNGO.OQ   BNGO.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
27 (estimated). 
    * The San Diego California-based  company is expected to
report  a
27.7% increase in revenue to $8.051 million from $6.3 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Bionano Genomics
Inc is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bionano
Genomics
Inc is $5.75​, above​ its last closing price of $1.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.12       -0.11      -0.11     Met     4.3
 Jun. 30 2022  -0.10       -0.09      -0.11     Missed  -20.4
 Mar. 31 2022  -0.09       -0.07      -0.11     Missed  -46.7​
 Dec. 31 2021  -0.06       -0.06      -0.08     Missed  -23.6
 ​​Sep.        -0.06       -0.06      -0.07     Missed  -30.6
 30 2021                                                
 Jun. 30 2021  -0.05       -0.05      -0.06     Missed  -32.6​
 Mar. 31 2021  -0.05       -0.04      -0.04     Met     11.1
 Dec. 31 2020  -0.05       -0.05      -0.05     Met     4.8
 This summary was machine generated February 24 at 12:46 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Bionano Genomics

See all news